Table 1.
Patient characteristics – discovery cohort
| Patient | Age group | Follow-up time [months] | Creatinine at time of biopsy [mg/dl] | Creatinine at follow-up [mg/dl] | eGFR (MDRD) at time of biopsy [ml/min/1.73 m 2 ] | eGFR (MDRD) at follow-up [ml/min/1.73 m 2 ] | Proteinuria at time of biopsy [g/d] | Proteinuria at follow-up [g/d] | Histological diagnosis | SD/PD | Endpoint | IFTA | GS | IFTA + GS = CREDI | II = INSCO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 62 | 0.84 | 0.88 | >60 | >60 | 1.9 | 3.2 | FSGS | Stable | - | 2 | 2 | 4 | 0 |
| 2 | 2 | 49 | 0.76 | 0.84 | >60 | >60 | 4.7 | 4.7 mg/dl | MCD | Stable | - | 0 | 0 | 0 | 0 |
| 3 | 4 | 63 | 0.79 | 0.75 | >60 | >60 | 500 mg/dl | 0.0 | MCD | Stable | - | 1 | 1 | 2 | 1 |
| 4 | 2 | 43 | 1.34 | 1.09 | 58.1 | >60 | 0.4 | 45.1 mg/dl | IGAN | Stable | - | 1 | 2 | 3 | 1 |
| 5 | 1 | 49 | 0.77 | 0.76 | >60 | >60 | 7.4 | 43.0 | FSGS | Stable | - | 0 | 2 | 2 | 0 |
| 6 | 2 | 39 | 0.8 | 0.75 | >60 | >60 | 1.6 | 0.2 | MCD | Stable | - | 1 | 1 | 2 | 0 |
| 7 | 1 | 31 | 1.0 | 0.96 | >60 | >60 | 1.3 | 14.8 mg/dl | IGAN | Stable | - | 1 | 1 | 2 | 1 |
| 8 | 3 | 52 | 0.93 | 0.97 | >60 | >60 | 1.3 | 263.3 mg/dl | IGAN | Stable | - | 1 | 1 | 2 | 0 |
| 9 | 1 | 51 | 1.89 | 0.91 | 44.8 | >60 | 42.0 | 42.0 | FSGS | Stable | - | 3 | 2 | 5 | 0 |
| 10 | 2 | 49 | 1.43 | 1.43 | 40.2 | 39.5 | 1.0 | 0.8 | IGAN | Stable | - | 3 | 3 | 6 | 1 |
| 11 | 2 | 50 | 1.56 | 1.8 | 51.8 | 42.9 | 1.2 | NA | IGAN | Stable | - | 2 | 2 | 4 | 0 |
| 12 | 3 | 67 | 1.42 | 2.28 | 51.6 | 29.3 | 2.7 | 4.6 | FSGS | Stable | - | 2 | 2 | 4 | 1 |
| 13 | 2 | 68 | 1.71 | 3.63 | 46.9 | 20.9 | 1.6 | 3.6 | IGAN | Progressive | 2xCrea | 3 | 2 | 5 | 1 |
| 14 | 1 | 51 | 1.02 | 3.5 | >60 | 21 | 12.0 | 17.5 | FSGS | Progressive | 2xCrea | 2 | 3 | 5 | 2 |
| 15 | 1 | 29 | 1.20 | 1.81 | 54.3 | 33.3 | 7.5 | 3.2 | IGAN | Stable | - | 2 | 3 | 5 | 0 |
| 16 | 4 | 42 | 1.50 | 7.02 | 34.5 | <20 | 8.5 | 8.0 | MGN | Progressive | ESRD | 2 | 2 | 4 | 1 |
| 17 | 1 | 49 | 1.87 | 10.1 | 33.4 | <20 | 6.5 | NA | RPGN | Progressive | ESRD | 2 | 1 | 3 | 2 |
| 18 | 2 | 48 | 1.27 | 4.02 | 47.9 | <20 | 6.5 | 1.3 | LN4 | Progressive | 2xCrea | 4 | 4 | 8 | 3 |
| 19 | 4 | 56 | 3.13 | 3.37 | <20 | <20 | 4.0 | 1.0 | MPGN II | Stable | - | 2 | 3 | 5 | 1 |
| 20 | 3 | 31 | 5.07 | 6.03 | <20 | <20 | 3.4 | 2.9 | MPA | Progressive | ESRD | 3 | 2 | 5 | 2 |
| 21 | 3 | n.a. | 4.67 | NA | <20 | NA | 10.6 | NA | IGAN | NA | NA | 1 | 4 | 5 | 1 |
| 22 | 2 | n.a. | 0.71 | NA | >60 | NA | 10.2 | NA | FSGS | NA | NA | 1 | 1 | 2 | 0 |
| 23 | 2 | n.a. | 1.12 | NA | >60 | NA | 0.5 | NA | IGAN | NA | NA | 3 | 2 | 5 | 1 |
| 24 | 2 | n.a. | 1.09 | NA | >60 | NA | 6.3 | NA | FSGS | NA | NA | 1 | 1 | 2 | 1 |
| 25 | 1 | n.a. | 1.0 | NA | >60 | NA | 1.2 | NA | IGAN | NA | NA | 0 | 0 | 0 | 0 |
| 26 | 3 | n.a. | 1.4 | NA | 52.6 | NA | 10.0 | NA | MCD | NA | NA | 1 | 1 | 2 | 0 |
| 27 | 4 | n.a. | 2.44 | NA | <20 | NA | 18.0 | NA | MCD | NA | NA | 2 | 1 | 3 | 1 |
| Median | 33 | 49 | 1.42 | 1.26 | 2.7 | 3.4 | 2.0 | 2.0 | 4.0 | 1.0 | |||||
| Mean | 39 | 49 | 1.66 | 2.64 | 4.0 | 5.5 | 1.9 | 2.0 | 3.8 | 0.9 | |||||
| SD | 17 | 11 | 1.12 | 2.65 | 2.9 | 6.0 | 1.0 | 0.9 | 1.8 | 0.9 | |||||
| Median S | 33 | 50 | 1.38 | 0.96 | 1.9 | 3.9 | 1.5 | 2.0 | 3.5 | 0.0 | |||||
| Median P | 33 | 49 | 1.71 | 6.03 | 6.5 | 3.3 | 2.5 | 2.0 | 5.0 | 2.0 | |||||
| Mean S | 39 | 49 | 1.4 | 1.29 | 3.2 | 3.9 | 1.5 | 1.8 | 3.3 | 0.4 | |||||
| Mean P | 40 | 48 | 2.19 | 6.15 | 5.8 | 6.3 | 2.7 | 2.3 | 5.0 | 1.8 | |||||
| SD S | 17 | 11 | 0.72 | 0.78 | 2.7 | 1.0 | NA | NA | NA | NA | |||||
| SD P | 19 | 12 | 1.65 | 2.59 | 2.9 | 7.5 | NA | NA | NA | NA | |||||
| p-value | n.s. | n.s. | n.s. | 0.01 | n.s. | n.s. | n.s. | n.s. | n.s. | 0.004 |
FSGS Focal-segmental glomerulosclerosis, MCD Minimal change disease, IGAN IgA-Nephropathy, MGN Membranous glomerulonephritis, RPGN Rapid progressive glomerulonephritis, LN4 Lupus nephritis WHO IV, MPGN II Membranoproliferative glomerulonephritis type II, MPA Microscopic polyangiitis, NA not applicable/ not assessed, IFTA interstitial fibrosis/tubular atrophy, GS glomerular sclerosis, II interstitial inflammation. Median, Mean and standard deviation (SD) for the patients with follow-up and from stable (S) and progressive (P) patients are shown at the bottom of the table. Age groups have been defined as follows: group 1 = age <30 years, 2 = 30–45, 3 = 46–60, 4 = age >60 years. p-values indicate statistical significance comparing clinical data (age, follow-up, creatinine, proteinuria) from stable and progressive patients.